Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies

Trial Profile

A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cirmtuzumab (Primary) ; Ibrutinib (Primary)
  • Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms CIRLL
  • Sponsors Oncternal Therapeutics, Inc.
  • Most Recent Events

    • 03 Dec 2019 According to an Oncternal Therapeutics media release, Interim data from this study will be presented at the American Society of Hematology (ASH) Annual Meeting that will be held December 7-10, 2019, in Orlando, FL.
    • 06 Nov 2019 Results released in the 61st Annual Meeting and Exposition of the American Society of Hematology.
    • 03 Oct 2019 According to an Oncternal Therapeutics media release, additional data from this clinical trial will be presented at a future medical conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top